Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 7/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | FAAH | O00519 | 2/20 | 0.52 |
| ▸ | CNR2 | P34972 | 2/20 | 0.52 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1604608 | 1.00 | CNR1 (0.64) | CNR1ALDH1A1FAAHCNR2TRPM8 | |
| SCHEMBL14746491 | 1.00 | CNR1 (0.64) | CNR1ALDH1A1FAAHCNR2TRPM8 | |
| SCHEMBL15951429 | 0.95 | CNR1 (0.64) | CNR1ALDH1A1FAAHCNR2TRPM8 | |
| SCHEMBL12478623 | 0.93 | CNR1 (0.73) | CNR1ALDH1A1FAAHCNR2TRPM8 | |
| SCHEMBL14739244 | 0.92 | CNR1 (0.62) | CNR1ALDH1A1FAAHCNR2TRPM8 | |
| SCHEMBL14739242 | 0.92 | CNR1 (0.62) | CNR1ALDH1A1FAAHCNR2TRPM8 | |
| SCHEMBL12685101 | 0.91 | CNR1 (0.69) | CNR1ALDH1A1FAAHCNR2TRPM8 | |
| SCHEMBL15124270 | 0.90 | CNR1 (0.64) | CNR1ALDH1A1FAAHCNR2TRPM8 | |
| SCHEMBL14752452 | 0.89 | CNR1 (0.68) | CNR1ALDH1A1FAAHCNR2TRPM8 | |
| SCHEMBL14752451 | 0.89 | CNR1 (0.68) | CNR1ALDH1A1FAAHCNR2TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200038342-A1 | FATTY ACID CYSTEAMINE CONJUGATES AND THEIR USE AS ACTIVATORS OF AUTOPHAGY | CATABASIS PHARMACEUTICALS, INC. | 2020-02-06 | — | — | US | disclosed |
| US-10251845-B2 | Fatty acid cysteamine conjugates and their use as activators of autophagy | CATABASIS PHARMACEUTICALS, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-20170258741-A1 | FATTY ACID CYSTEAMINE CONJUGATES AND THEIR USE AS ACTIVATORS OF AUTOPHAGY | CATABASIS PHARMACEUTICALS, INC. (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170073305-A1 | FATTY ACID AMIDES, COMPOSITIONS AND METHODS OF USE | CATABASIS PHARMACEUTICALS, INC. | 2017-03-16 | — | — | US | disclosed |
| EP-2949344-A2 | USE OF INTRACELLULAR ENZYMES FOR THE RELEASE OF COVALENTLY LINKED BIOACTIVES | Catabasis Pharmaceuticals, Inc. (US) | 2015-12-02 | — | — | EP | disclosed |
| US-20140315786-A1 | USE OF INTRACELLULAR ENZYMES FOR THE RELEASE OF COVALENTLY LINKED BIOACTIVES | CATABASIS PHARMACEUTICALS, INC. (US) | 2014-10-23 | — | — | US | disclosed |
| EP-2751071-A2 | FATTY ACID AMIDES, COMPOSITIONS AND METHODS OF USE | Milne, Jill C. (US) | 2014-07-09 | — | — | EP | disclosed |
| US-20130190327-A1 | BIS-FATTY ACID CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS INC (US) | 2013-07-25 | — | — | US | disclosed |
| WO-2013033602-A2 | FATTY ACID AMIDES, COMPOSITIONS AND METHODS OF USE | MILNE JILL C (US) | 2013-03-07 | — | — | WO | disclosed |
| US-20130059801-A1 | FATTY ACID AMIDES, COMPOSITIONS AND METHODS OF USE | CATABASIS PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20110082202-A1 | FATTY ACID ACIFRAN DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059801-A1 | FATTY ACID AMIDES, COMPOSITIONS AND METHODS OF USE | FASN, FADS1, ELOVL5 | CNR1 1072/4885ALDH1A1 810/4885FAAH 29/4885 |
| US-20170258741-A1 | FATTY ACID CYSTEAMINE CONJUGATES AND THEIR USE AS ACTIVATORS OF AUTOPHAGY | NDUFAB1, ATG7, HADHA | CNR1 2351/4885ALDH1A1 1342/4885FAAH 2282/4885 |
| US-20140315786-A1 | USE OF INTRACELLULAR ENZYMES FOR THE RELEASE OF COVALENTLY LINKED BIOACTIVES | GAA, GUSB, ACER2 | CNR1 3616/4885ALDH1A1 1139/4885FAAH 766/4885 |
| US-20130190327-A1 | BIS-FATTY ACID CONJUGATES AND THEIR USES | FASN, ELOVL1, ELOVL5 | CNR1 2557/4885ALDH1A1 610/4885FAAH 124/4885 |
| US-10251845-B2 | Fatty acid cysteamine conjugates and their use as activators of autophagy | NDUFAB1, ATG7, NLN | CNR1 2707/4885ALDH1A1 1672/4885FAAH 2320/4885 |
| US-20110082202-A1 | FATTY ACID ACIFRAN DERIVATIVES AND THEIR USES | FABP4, FASN, ELOVL6 | CNR1 1599/4885ALDH1A1 936/4885FAAH 159/4885 |
| US-20170073305-A1 | FATTY ACID AMIDES, COMPOSITIONS AND METHODS OF USE | FASN, FADS1, ELOVL5 | CNR1 1072/4885ALDH1A1 810/4885FAAH 29/4885 |
| US-20200038342-A1 | FATTY ACID CYSTEAMINE CONJUGATES AND THEIR USE AS ACTIVATORS OF AUTOPHAGY | ATG7, ATG4A, SLC27A1 | CNR1 1147/4885ALDH1A1 2685/4885FAAH 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.